Tue, 02/11/2010 - 08:19 by Prince damin
Washington -- Almost 100 drugs are in clinical trials or under federal review for use in treating Alzheimer's disease, pharmaceutical industry analysts say.
American pharmaceutical companies are researching 98 medicines for dementia, mostly Alzheimer's, a report released Monday by the Pharmaceutical Research and Manufacturers of America, the industry's main lobbying organization, said.
All are either in clinical trials or are being reviewed by the U.S. Food and Drug Administration, PhRMA said.
The work shows a major commitment to Alzheimer's, given that each new medicine costs, on average, more than $1 billion to research and develop, BusinesWire.com reported.
Fri, 31/07/2009 - 02:33 by Brian Orelli
The reverse merger to bring Merck (NYSE: MRK) and Schering-Plough (NYSE: SGP) together while attempting to avoid triggering a change in control provision in Schering and Johnson & Johnson's (NYSE: JNJ)
partnership was complex enough to warrant a full-page diagram to
explain it in the documents filed with the Securities and Exchange
Sat, 04/04/2009 - 21:26 by NeelamGoswami
New York, April 4:The US Food and Drug Administration has ordered 14 drug makers including Biogen Idec Inc., Pfizer Inc. and Sanofi-Aventis to stop using Internet search engines to promote their major drugs that fail to provide required safety information.